Harmony Biosciences
HRMY
32.59
-0.39
-1.18%
Harmony Biosciences
US · HRMY
#2681 by market cap
Listed 2020
32.59
-0.39
-1.18%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:02
Quant vs Street three independent views, side by side
StockVane factor grade
A+
Momentum strategy signal
Sell
Analyst consensus
Buy
Mostly aligned, one view stands apart.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
✦ Quant Analyst Revision Trend how this is computed
Deteriorating
2
■ Upgrades■ Downgrades
- 0 upgrades vs 2 downgrades among tracked analyst rating changes.
- Most recent: UBS moved from Buy to Hold on 2026-02-20.
Analyst consensus 8 analysts
Buy
Avg price target 47.50 +45.8%
Price target rangecurrent 32.59
Low30.00
Avg47.50
High60.00
Buy 63%
Hold 25%
Sell 13%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-11-12 | H.C. Wainwright | -- | Buy | 55.00 |
| 2026-11-06 | UBS | -- | Hold | 39.00 |
| 2026-11-05 | H.C. Wainwright | -- | Buy | 55.00 |
| 2026-11-04 | H.C. Wainwright | -- | Buy | 55.00 |
| 2026-11-03 | H.C. Wainwright | -- | Buy | 55.00 |
| 2026-10-29 | Mizuho Securities | -- | Buy | 49.00 |
| 2026-10-27 | H.C. Wainwright | -- | Buy | 55.00 |
| 2026-10-19 | Needham | -- | Buy | 50.00 |
| 2026-10-15 | Ladenburg Thalmann | -- | Buy | 55.00 |
| 2026-10-13 | H.C. Wainwright | -- | Buy | 55.00 |
| 2026-10-12 | Mizuho Securities | -- | Buy | 51.00 |
| 2026-10-12 | BofA Securities | -- | Sell | 30.00 |
| 2026-10-01 | Deutsche Bank | -- | Hold | 42.00 |
| 2026-09-25 | Mizuho Securities | -- | Buy | 51.00 |
| 2026-09-24 | Needham | -- | Buy | 50.00 |
| 2026-08-26 | Wolfe Research | -- | Buy | 60.00 |
| 2026-08-12 | H.C. Wainwright | -- | Buy | 55.00 |
| 2026-08-05 | Mizuho Securities | -- | Buy | 51.00 |
| 2026-08-05 | Deutsche Bank | -- | Hold | 39.00 |
| 2026-08-04 | Mizuho Securities | -- | Buy | 51.00 |
| 2026-08-04 | BofA Securities | -- | Sell | 30.00 |
| 2026-08-04 | Needham | -- | Buy | 50.00 |
| 2026-08-04 | H.C. Wainwright | -- | Buy | 55.00 |
| 2026-07-31 | Mizuho Securities | -- | Buy | 51.00 |
| 2026-07-27 | Mizuho Securities | -- | Buy | 50.00 |
Price target trend monthly average, last 3 years
Recent rating changes
| Date | Firm | Change | Target |
|---|---|---|---|
| 2026-02-20 | UBS | Buy → Hold | 46.00 |
| 2026-02-19 | Truist Financial | Buy → Hold | -- |
Earnings history price reaction on the day
| Period | Report date | Session | Options expected | Actual move |
|---|---|---|---|---|
| 2026/Q3 | 2026-11-04 | -- | ±15.14% | -7.04% (in line) |
| 2026/Q2 | 2026-08-04 | -- | ±16.79% | +8.93% (in line) |
| 2026/Q1 | 2026-05-07 | -- | ±14.03% | -4.15% (in line) |
| 2025/Q4 | 2026-02-24 | -- | ±14.00% | +4.91% (in line) |
| 2025/Q3 | 2025-11-04 | -- | ±11.00% | +4.74% (in line) |
| 2025/Q2 | 2025-08-05 | -- | ±17.96% | -1.69% (in line) |
| 2025/Q1 | 2025-05-06 | -- | ±13.45% | +6.98% (in line) |
| 2024/Q4 | 2025-02-25 | -- | ±13.47% | +8.16% (in line) |
| 2024/Q3 | 2024-10-29 | -- | ±16.69% | +16.06% (in line) |
| 2024/Q2 | 2024-08-06 | -- | ±23.30% | +6.18% (in line) |
| 2024/Q1 | 2024-04-30 | -- | ±13.46% | +5.68% (in line) |
| 2023/Q4 | 2024-02-22 | -- | ±17.42% | -4.70% (in line) |
"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.
Quote time 2026-11-20 20:02:36 · For reference only, not investment advice and not tailored to your situation.
Harmony Biosciences discussion 0 comments